Milrinone

Milrinone is an inhibitor of type 3 phosphodiesterases (PDEs), inhibiting recombinant PDE3A and PDE3B with IC50 values of 0.45 and 1 µM, respectively. It is selective for PDE3 over PDE1, PDE2, PDE4, PDE5, and PDE7 (IC50s = 263, >300, 17.5, 49.1, and 58.3 µM, respectively). Milrinone (0.1-1 mg/kg) has positive inotropic effects, increasing cardiac contractile force in anesthetized dogs with a concomitant increase in heart rate but not blood pressure. It also increases contractile force in models of propranolol- and verapamil-induced heart failure in anesthetized dogs when administered at an initial dose of 30 µg/kg followed by a continuous 3 µg/kg per minute infusion. Milrinone has vasodilatory effects as well, decreasing mean aortic pressure and increasing venous compliance in anesthetized dogs when administered at an initial dose of 10 µg/kg followed by a continuous 1.7-2.4 µg/kg per minute infusion. Formulations containing milrinone have been used in the treatment of heart failure.Formal Name: 1,6-dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile. CAS Number: 78415-72-2. Synonyms: WIN 47,203. Molecular Formula: C12H9N3O. Formula Weight: 211.2. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 0.3 mg/ml, DMSO: 0.5 mg/ml. lambdamax: 214, 270, 344 nm. SMILES: O=C(C(C#N)=C1)NC(C)=C1C2=CC=NC=C2. InChi Code: InChI=1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16). InChi Key: PZRHRDRVRGEVNW-UHFFFAOYSA-N.